Hot or Not, Stock Market Edition: 03/04/2025

By Dan Simms, Stock Reporter
March 3, 2025 6:26 PM UTC
Hot or Not, Stock Market Edition: 03/04/2025

Viral … Or downward spiral? We’ve got the inside scoop on the biggest market movers right now (in both directions):

HOT: Gilead Sciences (NASDAQ: GILD) has incredible near-term potential; Elastic NV (NYSE: ESTC) announces solid earnings.

NOT: Tesla’s (NASDAQ: TSLA) downtrend continues; Nvidia (NASDAQ: NVDA) remains in a unique sort of limbo. 

P.S. If you like updates like this, check out the biggest winners and biggest losers on WSZ. 

🔥 HOT: Security and logging SaaS company Elastic NV (NYSE: ESTC) gained 14.9% on Friday as it capitalized on its solid fourth-quarter earnings, albeit one day late. The company reported positive earnings on Thursday, beating its EPS projections by 33.8% and its revenue estimates by 3.5%. The stock, however, lost 2.2% as the market seemed unsure of what to make of the report. Well, the market decided on Friday that it liked the results after all. We also like ESTC and give it a B Zen Rating and a Buy recommendation. The company’s Sentiment rating is a solid B and its financials have been improving steadily over the last few quarters.

🥶 NOT: Tesla’s (NASDAQ: TSLA) tailslide took a small break on Friday as the stock gained a much-needed 3.9%. TSLA has lost 24.9% since the start of 2025 as investors question CEO Elon Musk’s ability to run the company while simultaneously acting as the head of the Department of Government Efficiency (DOGE). We see TSLA as a promising stock as the future of EVs continues to look bright, but we’re not as sure about its long-term success as we were in, say, 2023. We give TSLA a C Zen Rating, mostly due to the D rating it gets in Sentiment but also due to its recent negative momentum and increasingly shaky balance sheets.

🔥 HOT: Gilead Sciences (NASDAQ: GILD) gained 2.1% on Friday, as it continues to rally despite already gaining 23.4% YTD and 56.2% over the last year. The company’s growth has been driven primarily by sales of Biktravey — its flagship HIV drug — which have increased by 21.4% over the last year. It’s hard for us to wrap our heads around GILD’s potential for continued growth, which is why we give the stock an A Zen Rating and a Strong Buy recommendation. The company gets an outstanding A rating for Value and B ratings in other key areas like Financials, Safety, and Sentiment. No matter how you look at it, GILD is a must buy.

🥶 NOT: Nvidia (NASDAQ: NVDA) is in a weird spot nearly two months into 2025. The stock is down 8.2% YTD after a 3.9% gain on Friday, but the real issue is no one is sure whether or not to trust the positive metrics that came out of its most recent earnings report. The numbers are good. The company surpassed Wall Street’s estimates for both EPS and revenue and announced that its sales had doubled in the automotive sector. Analysts are split on whether they think the AI boom will continue or if some combination of the bubble popping and Trump’s tariffs will stymie NVDA’s growth. We’re not sure where NVDA is headed either, which is why we give it a C Zen Rating. The company gets an A rating for its outstanding financials, but it’s not the safe growth play it’s been for the last two years.

What to Do Next?

Want to get in touch? Email us at news@wallstreetzen.com.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.